DrugTrek P.C.
DrugTrek is a micro small-to-medium enterprise (SME) and a Fleming and Uni-Pharma spinoff founded in 2025. DrugTrek was created following years of collaboration between the BSRC Fleming, a leading Research Institute in Greece, and UniPharma, one of the largest pharmaceutical companies in Greece. Their collaborative research and development on Autotaxin and small-molecule inhibitors have led to an extensive intellectual property (IP) portfolio and to EL244, a promising clinical candidate for the treatment of IPF and other ILDs, an unmet medical need. DrugTreks' ambition is to bring EL244 to the clinic and alleviate the heavy societal toll of fibrosis, while exploiting the momentum of the IPF financial ecosystem and commercializing the related IP.